IW 400

September 16, 2026 Viktor Zarev 0 min read
  1. Senate grills surgeon general nominee on vaccine views. 
  2. States plow federal rural health funds into tech startups. 
  3. FDA takes feedback on therapy with psychedelic drugs. 
  4. Growing pains plague start of CMS’s prior auth program. 
  5. CMS extends ACCESS payment program to new conditions.
  6. How is AI changing biotech hiring?
  7. For-profit health plans fall short in new ratings survey. 
  8. Arkansas pharmacies try new legal tack vs. Express Scripts.
  9. New measles death reported in Pennsylvania. 
  10. Spotlight on five biotechs making product launches.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Structural Heart October 5, 2026

The Double Firsts of Edwards’ Autus Approval October 5, 2026

Children born with congenital pulmonary valve disease no longer need repeat surgeries throughout childhood with the FDA approval of Edwards Lifesciences' Autus Size-Adjustable Valve.

Cardiology Practices October 2, 2026

Can Rural Cardiology Be Revived? October 2, 2026

Nearly nine in ten rural counties lack a cardiologist and a new survey of the physicians serving the other 10% revealed that the issue runs deeper than […]

Cardiology Pharmaceuticals October 1, 2026

A New King of The GLP-1s Could Be Crowned October 1, 2026

Ladies and gents, Eli Lilly has outdone itself again, with the Phase 3 results of its triple GLP-1/GIP/glucagon receptor agonist, retatrutide, showing astonishing weight loss results for patients with obesity.